December 3, 2019 8:47am

News: Japanese pharmaceutical company Astellas Pharma is acquiring gene therapy biotech company Audentes Therapeutics (BOLD -$0.42 to $28.61 at close) for $3 billion. Under terms of the deal, Astellas will pay $60 per share; BOLD’ stock jumped +106.40% to $59.05 in after-market trading.

Pre-open indications: SELL – VCEL, SLDB, PSTI on strength and BOLD to cash out; BUY – SAGE, RGNX and VYGR

It’s an honor to be considered the “canary in the (sectors) coal mine”!  I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!


Who is feeding your portfolio profits - RMi’s pre-open indicators or should be!


Dow futures are DOWN -0.85% (-237 points), S&P futures are DOWN -0.67% (-21 point) and NASDAQ futures are DOWN -0.92% (-77 points)


U.S. stock index futures dropped on Tuesday after President Trump said a China trade deal may not happen until after the 2020 election;

European stocks hovered around the flat line T after President Trump said it’s better to wait strike a trade deal with China as the pan-European Stoxx 600 traded below the flat line in early afternoon trade;

Asia Pacific markets mostly fell following negative trade developments, reinstatement of tariffs on U.S. steel and aluminum imports from Brazil and Argentina. Australia led losses among regional stocks when the Reserve Bank of Australia kept its main cash rate at a record low of 0.75%;


Data Docket: the latest quarterly financial report will be released at 10 a.m. ET, with light vehicle sales figures for November set to follow slightly later in the session.



The multiple scenarios of the China trade deal being completed won’t probably get done before or just after the election … it is being bandied about …

“In some ways, I like the idea of waiting until after the election for the China deal, but they want to make a deal now and we will see whether or not the deal is going to be right,” Trump told reporters earlier on Tuesday. When asked if he had a deal deadline, he added: “I have no deadline, no ... In some ways, I think it is better to wait until after the election if you want to know the truth.”


Monday night’s newsletter heading: “right again as the sector dives.”

I also stated, “I was time for many to clear their minds of machine-driven optimism and face the realities of this market and the timing of year end approaching.”

  • The NASDAQ closed DOWN -97.48 points (-1.12%);
  • The IBB closed down -1.20% while the XBI closed down -1.33%
  • The close was negative with an A/D line of 14/26, 2 flats, 1 reversed merged (HSGX) and 2 acquired;


Review the context of Q4’s market – so far:

  • December register 1 negative close … so far
  • November registered 1 holiday, 12 positive and 8 negative close;
  • October registered 10 positive, 1 neutral and 14 negative closes;


Companies in my headlights – It’s your decision; I provide an idea and context:

Pre-open indications: SELL – VCEL, SLDB, PSTI on strength and BOLD to cash out; BUY – SAGE, RGNX and VYGR


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.